STAA Stock Forecast 2025-2026
Distance to STAA Price Targets
STAA Price Momentum
10 Quality Stocks Worth Considering Now
Researching STAAR (STAA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on STAA and similar high-potential opportunities.
Latest STAA Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, STAA has a neutral consensus with a median price target of $17.00 (ranging from $13.00 to $27.00). The overall analyst rating is Buy (6.6/10). Currently trading at $17.88, the median forecast implies a -4.9% downside. This outlook is supported by 3 Buy, 10 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STAA Analyst Ratings
STAA Price Target Range
Latest STAA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STAA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | Wells Fargo | Equal-Weight | Initiates | $17.00 | |
| Mar 18, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $17.00 |
| Feb 27, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Feb 13, 2025 | Canaccord Genuity | Jon Young | Hold | Maintains | $17.00 |
| Feb 12, 2025 | William Blair | Margaret Kaczor | Market Perform | Downgrade | $0.00 |
| Feb 12, 2025 | Stephens & Co. | Mason Carrico | Equal-Weight | Reiterates | $28.00 |
| Feb 12, 2025 | Stifel | Thomas Stephan | Buy | Maintains | $20.00 |
| Feb 12, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Feb 12, 2025 | Piper Sandler | Matt O'Brien | Neutral | Maintains | $16.00 |
| Jan 7, 2025 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Dec 9, 2024 | Canaccord Genuity | Jon Young | Hold | Maintains | $28.00 |
| Nov 1, 2024 | Canaccord Genuity | Jon Young | Hold | Maintains | $31.00 |
| Oct 31, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Sep 19, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Aug 26, 2024 | Stifel | Thomas Stephan | Buy | Maintains | $44.00 |
| Aug 8, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
| Aug 8, 2024 | Canaccord Genuity | Jon Young | Hold | Maintains | $41.00 |
| Jul 15, 2024 | Morgan Stanley | Patrick Wood | Underweight | Downgrade | $37.00 |
| Jul 15, 2024 | BTIG | Ryan Zimmerman | Buy | Maintains | $53.00 |
| Jul 15, 2024 | Needham | David Saxon | Hold | Reiterates | $0.00 |
Staar Surgical Company (STAA) Competitors
The following stocks are similar to STAAR based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Staar Surgical Company (STAA) Financial Data
Staar Surgical Company has a market capitalization of $858.26M with a P/E ratio of 49.7x. The company generates $313.90M in trailing twelve-month revenue with a -6.4% profit margin.
Revenue growth is -35.8% quarter-over-quarter, while maintaining an operating margin of -56.9% and return on equity of -5.2%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Staar Surgical Company (STAA) Business Model
About Staar Surgical Company
Develops implantable lenses for vision correction.
Staar Surgical makes money by designing, manufacturing, and marketing implantable lenses, particularly the Implantable Collamer Lens (ICL) for refractive surgery. Their products target common vision defects like myopia and astigmatism, offering alternatives to traditional corrective methods and generating revenue through sales to ophthalmologists and eye care facilities worldwide.
Based in California, Staar Surgical is a leader in the ophthalmology sector, focusing on innovative technologies that enhance visual health. The company's commitment to research and development positions it as a key player in advanced eye care solutions, catering to a growing global demand for effective vision correction options.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
1,157
CEO
Mr. Stephen C. Farrell CFA
Country
United States
IPO Year
1992
Website
www.staar.comStaar Surgical Company (STAA) Latest News & Analysis
Latest News
Market volatility has increased since early April due to uncertainty over inflation, interest rates, quarterly reports, and the effects of tariffs and a global trade war on the U.S. economy.
Increased market volatility signals heightened risk for investments, affecting stock prices and investor sentiment due to uncertainties around inflation, interest rates, and trade tensions.
Pomerantz LLP is investigating claims for STAAR Surgical Company (NASDAQ:STAA) investors. Interested parties can contact Danielle Peyton for more information.
The investigation into STAAR Surgical could signal potential legal risks, impacting stock performance and investor sentiment, thus affecting market value and investment decisions.
STAAR Surgical Company has promoted Warren Foust to President and Chief Operating Officer to enhance its leadership structure and address market needs effectively.
Leadership changes can signal a company's strategic shift or focus, impacting operational efficiency and market responsiveness, which may influence investor confidence and stock performance.
Levi & Korsinsky is investigating STAAR Surgical Company (NASDAQ:STAA) for potential federal securities law violations after the company reported disappointing Q4 2024 earnings due to weak demand in China.
STAAR Surgical's investigation for potential securities law violations following poor earnings and weak demand signals heightened risk and could impact stock performance.
Levi & Korsinsky is investigating STAAR Surgical (NASDAQ:STAA) for potential federal securities law violations following disappointing Q4 2024 earnings due to weak demand in China and fewer refractive procedures.
The investigation into STAAR Surgical for possible securities law violations, combined with weak Q4 2024 earnings and declining demand, raises concerns about the company's future performance and stock stability.
Insiders Are Loading Up on These 6 Stocks Now
1 month agoAn American semiconductor company saw a significant insider purchase of nearly $20 million in the past week, indicating potential confidence in the firm's performance.
A $20 million insider purchase in a semiconductor firm signals strong confidence in the company's future, potentially boosting investor sentiment and stock performance.
Frequently Asked Questions About STAA Stock
What is Staar Surgical Company's (STAA) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Staar Surgical Company (STAA) has a median price target of $17.00. The highest price target is $27.00 and the lowest is $13.00.
Is STAA stock a good investment in 2025?
According to current analyst ratings, STAA has 3 Buy ratings, 10 Hold ratings, and 1 Sell ratings. The stock is currently trading at $17.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STAA stock?
Wall Street analysts predict STAA stock could reach $17.00 in the next 12 months. This represents a -4.9% decrease from the current price of $17.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Staar Surgical Company's business model?
Staar Surgical makes money by designing, manufacturing, and marketing implantable lenses, particularly the Implantable Collamer Lens (ICL) for refractive surgery. Their products target common vision defects like myopia and astigmatism, offering alternatives to traditional corrective methods and generating revenue through sales to ophthalmologists and eye care facilities worldwide.
What is the highest forecasted price for STAA Staar Surgical Company?
The highest price target for STAA is $27.00 from at , which represents a 51.0% increase from the current price of $17.88.
What is the lowest forecasted price for STAA Staar Surgical Company?
The lowest price target for STAA is $13.00 from at , which represents a -27.3% decrease from the current price of $17.88.
What is the overall STAA consensus from analysts for Staar Surgical Company?
The overall analyst consensus for STAA is neutral. Out of 17 Wall Street analysts, 3 rate it as Buy, 10 as Hold, and 1 as Sell, with a median price target of $17.00.
How accurate are STAA stock price projections?
Stock price projections, including those for Staar Surgical Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.